10-Q: Acutus Medical Reports Q3 2024 Results, Revenue Jumps on Medtronic Partnership

Acutus Medical's Q3 2024 results show a significant increase in revenue driven by its manufacturing agreement with Medtronic, despite continued losses from discontinued operations.

Summary

• Acutus Medical reported its financial results for the third quarter of 2024, showing a substantial increase in revenue to $5.3 million, compared to $2.1 million in the same period last year.
• This revenue growth is primarily attributed to the company's role as a manufacturer of left-heart access products for Medtronic.
• The company's gross profit margin improved significantly to 7% in Q3 2024, compared to a negative 53% in Q3 2023, due to improved manufacturing efficiencies.
• Despite the revenue increase, Acutus Medical continues to experience losses, with a net loss from continuing operations of $0.8 million for the quarter and $3.2 million for the nine months ended September 30, 2024.
• Discontinued operations, related to the company's mapping and ablation businesses, resulted in a net loss of $4.8 million for the quarter and $4.9 million for the nine months ended September 30, 2024.
• The company's restructuring efforts, initiated in late 2023, are substantially complete, with $24.1 million of the estimated $21.0 million to $32.0 million in pre-tax restructuring and exit-related charges recognized as of September 30, 2024.
• Acutus Medical's cash, cash equivalents, restricted cash, and marketable securities totaled $12.6 million as of September 30, 2024, compared to $29.4 million at the end of 2023.
• The company's accumulated deficit stood at $608.1 million as of September 30, 2024.
• Management believes the company's current cash and anticipated earnouts are sufficient to fund operations for at least the next 12 months.

Sentiment

Score: 5

Explanation: The sentiment is neutral to slightly positive. While the company shows significant revenue growth and improved gross margins, it continues to experience losses, has a large accumulated deficit, and is heavily reliant on a single customer. The delisting from Nasdaq is also a negative factor. The restructuring is a positive step, but its long-term impact remains to be seen.

Positives

• The company's revenue increased significantly due to its manufacturing agreement with Medtronic.
• Gross profit margin improved substantially, indicating better operational efficiency.
• Losses from continuing operations decreased compared to the same period last year.
• The company has received $13.2 million in Net Sales Earnout payments during the nine months ended September 30, 2024.
• The restructuring is substantially complete, which should lead to reduced operating expenses.

Negatives

• The company continues to incur net losses, both from continuing and discontinued operations.
• Cash reserves have decreased significantly from $29.4 million at the end of 2023 to $12.6 million as of September 30, 2024.
• The company has an accumulated deficit of $608.1 million.
• The company's stock was delisted from Nasdaq and now trades on the OTC Pink Market.
• The company is dependent on Medtronic for revenue generation and is vulnerable if Medtronic's sales decline.

Risks

• Acutus Medical is heavily reliant on Medtronic for revenue, and any decrease in Medtronic's sales or termination of the agreement would significantly impact the company.
• The company's manufacturing operations are subject to supply chain risks, including potential disruptions and delays.
• The company may not achieve the anticipated cost savings or other benefits from the restructuring.
• The company faces intense competition in the medical device industry.
• The company's financial results may fluctuate due to various factors, including inventory write-offs, component costs, and inflation.
• The company has a significant amount of debt, which could impact its financial flexibility.
• The company is subject to legal proceedings, including the Biotronik settlement, which could result in additional costs.

Future Outlook

Management believes the company's current cash, cash equivalents, and marketable securities, along with anticipated cash earnouts from Medtronic, are sufficient to fund operations for at least the next 12 months.

Management Comments

• Management believes the Restructuring is substantially complete.
• Management continues to review cost improvement opportunities and pathways to reduce expenses and cash burn.
• Management believes the company's current cash and anticipated earnouts are sufficient to fund operations for at least the next 12 months.

Industry Context

Acutus Medical's shift to solely manufacturing for Medtronic reflects a trend of smaller medical device companies partnering with larger players for distribution and manufacturing. The company's focus on left-heart access products aligns with the growing demand for minimally invasive cardiac procedures.

Comparison to Industry Standards

• Acutus Medical's revenue growth of 156% in Q3 2024 is significant, but it is important to note that this is from a low base and is driven by a specific manufacturing agreement with Medtronic, not organic sales growth of its own products.
• Compared to larger medical device companies like Medtronic, Abbott, and Boston Scientific, Acutus Medical's revenue is still relatively small, and its profitability is significantly lower.
• The company's gross margin improvement to 7% is a positive sign, but it is still below the industry average for medical device manufacturers, which typically ranges from 50% to 70%.
• The company's continued losses and negative cash flow are concerning and highlight the challenges of smaller medical device companies in achieving profitability.
• The delisting from Nasdaq and move to the OTC Pink Market is a significant setback and indicates the company's financial struggles.
• The company's reliance on a single customer, Medtronic, is a major risk factor, unlike larger companies with diversified customer bases.

Legal Proceedings

• A securities class action lawsuit against the company and certain officers was dismissed with prejudice after the plaintiff voluntarily dismissed the appeal.
• The company entered into a Settlement Agreement with Biotronik, resolving an arbitration dispute and requiring an initial payment of approximately $2.5 million and potential contingent payments.

Related Party Transactions

• The company has a credit agreement with related parties Deerfield Private Design Fund III, L.P. and Deerfield Partners, L.P.

Stakeholder Impact

• Shareholders have experienced a significant loss in value due to the delisting from Nasdaq and the company's financial struggles.
• Employees have been affected by the restructuring, with a 65% reduction in workforce.
• Customers of the company's legacy products have been impacted by the discontinuation of those products.
• Medtronic, as a key partner, is significantly impacted by the company's performance.
• Creditors are exposed to the company's financial risks and debt obligations.

Next Steps

• The company will continue to manufacture left-heart access products for Medtronic.
• The company will continue to explore strategic alternatives for its mapping and ablation businesses.
• The company will continue to monitor its financial performance and seek cost improvement opportunities.
• The company will continue to manage its debt obligations and liquidity.

Key Dates

Keywords

Acutus Medical, Medtronic, left-heart access, manufacturing, restructuring, revenue, net loss, gross profit, OTC Pink Market, delisting, financial results, medical devices, electrophysiology, supply chain, Biotronik